Factors Predicting Poor Response to Initial Therapy in Benign Childhood Epilepsy with Centrotemporal Spikes (BCECTS)

Yoon Kyoung Park1, So-Hee Eun1, Baik-Lin Eun1

  • 1Department of Pediatrics, Korea University College of Medicine, Seoul, Korea.

Insights

Benign childhood epilepsy with centrotemporal spikes (BCECTS) can be challenging to treat. Seizure onset before age 5 and a history of febrile seizures are key predictors of poor response to initial antiepileptic drug (AED) therapy in these children.

Area of Science:

  • Pediatric Neurology
  • Epileptology
  • Clinical Pediatrics

Background:

  • Benign childhood epilepsy with centrotemporal spikes (BCECTS) is the most common pediatric focal epilepsy.
  • While typically having positive outcomes, some BCECTS patients experience recurrent seizures requiring antiepileptic drug (AED) treatment.
  • Identifying factors for treatment resistance is crucial for optimizing patient care.

Purpose of the Study:

  • To identify risk factors associated with a poor response to initial antiepileptic drug (AED) therapy in children diagnosed with BCECTS.
  • To differentiate between patients requiring one versus multiple AEDs for seizure control.

Main Methods:

  • Retrospective review of 57 BCECTS patients treated with AEDs between 2008 and 2013.
  • Patients were categorized into two groups based on the number of AEDs used (1 AED vs. 2 AEDs).
  • Clinical characteristics were analyzed to determine independent risk factors for treatment resistance.

Main Results:

  • 72% of patients responded to a single AED, while 28% required two AEDs.
  • Seizure onset before age 5 (OR: 5.65) and a history of febrile seizures (OR: 4.97) were significant independent risk factors for poor initial AED response.
  • EEG findings, brain MRI abnormalities, seizure frequency, and family history did not predict treatment response.

Conclusions:

  • Approximately 28% of BCECTS patients exhibit a poor response to initial AED therapy.
  • Early seizure onset (prior to age 5) and a history of febrile seizures are critical predictors of inadequate response to initial AEDs in BCECTS.
  • These findings aid in predicting treatment outcomes and guiding therapeutic strategies for pediatric epilepsy management.
Abstract

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.6K
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
1.1K
Seizures: Classification01:13

Seizures: Classification

Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
2.1K
Electroconvulsive Therapy01:30

Electroconvulsive Therapy

Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
2.0K
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
1.2K
Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
3.3K